Evidence map›Paper›PMID 32765015›Full record

ArticleInfection and drug resistance2020

Disk-Diffusion Testing Is an Inappropriate Screening Tool for Cephalosporin-Resistant Gonorrhoea Strains in Clinical Practice in China.

Yan Han, Yue-Ping Yin, Wen-Qi Xu, Xiao-Yu Zhu, Shao-Chun Chen, Xiu-Qin Dai, Li-Gang Yang, Bang-Yong Zhu, Na Zhong, Wen-Ling Cao and 6 more

Open access · goldAbstract read
In one paragraph

Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 2 countries.

Yan HanInstitute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, People's Republic of China.
Yue-Ping YinInstitute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, People's Republic of China.ORCID 0000-0003-1700-2750
Wen-Qi XuInstitute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, People's Republic of China.
Xiao-Yu ZhuInstitute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, People's Republic of China.
Shao-Chun ChenInstitute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, People's Republic of China.ORCID 0000-0002-6447-928X
Xiu-Qin DaiInstitute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, People's Republic of China.
Li-Gang YangDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Bang-Yong ZhuInstitute of Dermatology, Nanning, Guangxi Autonomous Region, People's Republic of China.
Na ZhongHainan Provincial Center for STD/Skin Disease Control and Prevention, Haikou, Hainan, People's Republic of China.
Wen-Ling CaoGuangzhou Institute of Dermatology, Guangzhou, Guangdong, People's Republic of China.
Xiao-Hui ZhangDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Zhi-Zhou WuJiangmen Dermatology Hospital, Jiangmen, Guangdong, People's Republic of China.
Liu-Feng YuanBeijing Ditan Hospital Capital Medical University, Beijing, People's Republic of China.
Zhong-Jie ZhengTianjin Center for Disease Control and Prevention, Tianjin, People's Republic of China.
Jun LiuHarvard Medical School, Boston, MA, USA.ORCID 0000-0002-1546-0224
Xiang-Sheng ChenInstitute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, People's Republic of China.ORCID 0000-0003-3927-2065
Chinese Center For Disease Control and Prevention · CNGuangdong Provincial People's Hospital · CNCapital Medical University · CNGuangzhou Institute of Dermatology · CNHainan Center for Disease Control & Prevention · CNHarvard University · USJiangmen Central Hospital · CNThe People's Hospital of Guangxi Zhuang Autonomous Region · CNTianjin Centers for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeInjectable ceftriaxone and oral cefixime are the last agents effective against

methodsA total of 1,633 consecutive clinical isolates of

resultsThe prevalence of isolates with decreased susceptibility to ceftriaxone and cefixime was 12.1% (198 of 1,633) and 12.7% (208 of 1,633), respectively, using KB disk-diffusion tests. The prevalence of isolates with decreased susceptibility was 9.9% (129 of 1,306) for ceftriaxone and 9.9% (129 of 1,305) for cefixime using agar-dilution AST. The categorical agreement of these two methods was 80.9% for both ceftriaxone and cefixime. Compared to agar-dilution AST, the sensitivity of the KB test for detecting

conclusionAlthough KB tests are easy to carry out in clinical practice, their ability to detect cephalosporin-resistant gonorrhoea strains is limited. This method is not an appropriate selection for screening cephalosporin-resistant gonorrhoea strains in clinical practice in China.

Indexed as

agar-dilution methodKirby–Bauer disk-diffusion testsNeisseria gonorrhoeaescreensusceptibility

Identifiers

PMID32765015
PMCPMC7381770
OpenAlexW3042254098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.